Windlas BiotechNSE:WINDLAS +0.94%89 EBITDA Margin % is 12.43% as of Mar. 2026, which is 9% below its 10-year median of 13.65. GuruFocus rates NSE:WINDLAS with a GF Score™ of 89/100 and a GF Value™ of ₹936.76 (Fairly Valued). The stock has 1 warning sign investors should review. Among 955 Drug Manufacturers companies, Windlas Biotech ranks better than 52.77% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Windlas Biotech's EBITDA for the
three
months ended in Mar. 2026 was ₹296 Mil. Windlas Biotech's Revenue for the
three
months ended in Mar. 2026 was ₹2,385 Mil. Therefore, Windlas Biotech's EBITDA margin for the quarter that ended in Mar. 2026 was 12.43%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Windlas Biotech EBITDA Margin % Related Terms
Windlas Biotech EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Windlas Biotech's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Windlas Biotech's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Windlas Biotech EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Windlas Biotech's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Windlas Biotech's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Windlas Biotech (NSE:WINDLAS) has a EBITDA Margin % of 12.43% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Windlas Biotech and its competitors. This is near median its historical median of 13.65. Over the past decade, Windlas Biotech's EBITDA Margin % has ranged from 8.44 to 29.99. According to the industry distribution chart, Windlas Biotech ranks #451 out of 955 companies in the Drug Manufacturers industry, placing it in the top 47.2%.
Is Windlas Biotech's EBITDA Margin % too high?
Windlas Biotech's current EBITDA Margin % of 12.43% is near median its 10-year median of 13.65. Over the past 10 years, this metric has ranged from a low of 8.44 to a high of 29.99. The Drug Manufacturers industry median EBITDA Margin % is 12.39. Windlas Biotech's value of 12.43% is 0.3% above this industry median. Based on the distribution chart, Windlas Biotech ranks #451 out of 955 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Windlas Biotech has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Windlas Biotech's EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Windlas Biotech ranks #451 out of 955 companies for EBITDA Margin %. This puts Windlas Biotech in the upper half of its industry. The industry median EBITDA Margin % is 12.39. Windlas Biotech's value of 12.43% is 0.3% above this benchmark. Historically, Windlas Biotech's own EBITDA Margin % has ranged from 8.44 to 29.99 over the past decade. While the company's 10-year median is 13.65 vs. the industry median of 12.39, Windlas Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.39, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Windlas Biotech's current EBITDA Margin % of 12.43% is 0.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Windlas Biotech and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Windlas Biotech's current EBITDA Margin % is 12.43%, which is near median its own 10-year median of 13.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Windlas Biotech stock overvalued right now?
Based on GuruFocus' analysis, Windlas Biotech (NSE:WINDLAS) is currently considered Fairly Valued. The stock's GF Value™ is ₹936.76, compared to a current price of ₹863.80 — trading 7.8% below its estimated fair value. The current EBITDA Margin % is 12.43%, which is near median its 10-year median of 13.65 and 0.3% above the Drug Manufacturers industry median of 12.39. Windlas Biotech's overall GF Score™ is 89/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Windlas Biotech (NSE:WINDLAS), the current EBITDA Margin % is 12.43% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Windlas Biotech (NSE:WINDLAS) Overvalued in 2026?
Based on GuruFocus' analysis, Windlas Biotech stock appears to be undervalued.
The current stock price of ₹863.80 is trading 7.8% below its estimated GF Value™ of ₹936.76.
GuruFocus considers Windlas Biotech to be Fairly Valued.
Key valuation signals for NSE:WINDLAS:
EBITDA Margin %: 12.43% (near median its 10-year median of 13.65)
GF Value™: ₹936.76 vs. price of ₹863.80 (7.8% below fair value)
Industry Position: 0.3% above the Drug Manufacturers median (#451 of 955)
No single metric tells the full story. See the NSE:WINDLAS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Windlas Biotech Ltd is a pharmaceutical formulation contract development and manufacturing organization. The company offers a range of CDMO services from product discovery to product development, licensing, and commercial manufacturing of generic products including complex generics.
89GF Score
Get the complete analysis for NSE:WINDLAS
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:WINDLAS has been successfully added to your 
